Literature DB >> 30996779

Discovery of Pyrido[3',2':5,6]thiopyrano[4,3-d]pyrimidine-Based Antiproliferative Multikinase Inhibitors.

Silvia Salerno1, Elisabetta Barresi1, Aída Nelly García-Argáez2, Sabrina Taliani1, Francesca Simorini1, Giorgio Amendola3, Stefano Tomassi3, Sandro Cosconati3, Ettore Novellino4, Federico Da Settimo1, Anna Maria Marini1, Lisa Dalla Via2.   

Abstract

Protein kinases dysregulation is extremely common in cancer cells, and the development of new agents able to simultaneously target multiple kinase pathways involved in angiogenesis and tumor growth may offer several advantages in the treatment of cancer. Herein we report the discovery of new pyridothiopyranopyrimidine derivatives (2-4) showing high potencies in VEGFR-2 KDR inhibition as well as antiproliferative effect on a panel of human tumor cell lines. Investigation on the selectivity profile of the representative 2-anilino-substituted compounds 3b, 3i, and 3j revealed a multiplicity of kinase targets that should account for the potent antiproliferative effect produced by these pyridothiopyranopyrimidine derivatives.

Entities:  

Year:  2019        PMID: 30996779      PMCID: PMC6466516          DOI: 10.1021/acsmedchemlett.8b00499

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  28 in total

1.  Synthesis, in vitro antiproliferative activity and DNA-interaction of benzimidazoquinazoline derivatives as potential anti-tumor agents.

Authors:  L Dalla Via; O Gia; S M Magno; A Da Settimo; A M Marini; G Primofiore; F Da Settimo; S Salerno
Journal:  Farmaco       Date:  2001-03

2.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

Review 3.  Angiogenesis in life, disease and medicine.

Authors:  Peter Carmeliet
Journal:  Nature       Date:  2005-12-15       Impact factor: 49.962

4.  Mitochondrial permeability transition induced by novel pyridothiopyranopyrimidine derivatives: potential new antimitochondrial antitumour agents.

Authors:  Lisa Dalla Via; Anna Maria Marini; Silvia Salerno; Antonio Toninello
Journal:  Biochem Pharmacol       Date:  2006-09-18       Impact factor: 5.858

5.  Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.

Authors:  Victor J Cee; Alan C Cheng; Karina Romero; Steve Bellon; Christopher Mohr; Douglas A Whittington; Annette Bak; James Bready; Sean Caenepeel; Angela Coxon; Holly L Deak; Jenne Fretland; Yan Gu; Brian L Hodous; Xin Huang; Joseph L Kim; Jasmine Lin; Alexander M Long; Hanh Nguyen; Philip R Olivieri; Vinod F Patel; Ling Wang; Yihong Zhou; Paul Hughes; Stephanie Geuns-Meyer
Journal:  Bioorg Med Chem Lett       Date:  2008-11-20       Impact factor: 2.823

Review 6.  Tumor angiogenesis.

Authors:  Robert S Kerbel
Journal:  N Engl J Med       Date:  2008-05-08       Impact factor: 91.245

Review 7.  Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs.

Authors:  S B Fox; G Gasparini; A L Harris
Journal:  Lancet Oncol       Date:  2001-05       Impact factor: 41.316

Review 8.  Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.

Authors:  Scott M Wilhelm; Lila Adnane; Philippa Newell; Augusto Villanueva; Josep M Llovet; Mark Lynch
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

9.  Dialkylaminoalkylindolonaphthyridines as potential antitumour agents: synthesis, cytotoxicity and DNA binding properties.

Authors:  Lisa Dalla Via; Ornella Gia; Sebastiano Marciani Magno; Antonio Da Settimo; Giampaolo Primofiore; Federico Da Settimo; Francesca Simorini; Anna Maria Marini
Journal:  Eur J Med Chem       Date:  2002-06       Impact factor: 6.514

Review 10.  Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

Authors:  Alessandro Morabito; Ermelinda De Maio; Massimo Di Maio; Nicola Normanno; Francesco Perrone
Journal:  Oncologist       Date:  2006 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.